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Abstract Polyneuropathy is a disabling condition of the
peripheral nerves, characterized by symmetrical distal
numbness and paresthesia, often accompanied with pain
and weakness. Although the disease is often encountered in
neurological clinics and is well known by physicians,
incidence and prevalence rates are not well known. We
searched EMBASE, Medline, Web-of-science, Cochrane,
PubMed Publisher, and Google Scholar, for population-
based studies investigating the prevalence of polyneu-
ropathy and its risk factors. Out of 5119 papers, we iden-
tified 29 eligible studies, consisting of 11 door-to-door
survey studies, 7 case–control studies and 11 cohort/data-
base studies. Prevalence of polyneuropathy across these
studies varies substantially. This can partly be explained by
differences in assessment protocols and study populations.
The overall prevalence of polyneuropathy in the general
population seems around 1 % and rises to up to 7 % in the
elderly. Polyneuropathy seemed more common in Western
countries than in developing countries and there are indi-
cations that females are more often affected than males.
Risk factor profiles differ across countries. In developing
countries communicable diseases, like leprosy, are more
common causes of neuropathy, whereas in Western coun-
tries especially diabetes, alcohol overconsumption, cyto-
static drugs and cardiovascular disease are more commonly
associated with polyneuropathy. In all studies a substantial
proportion of polyneuropathy cases (20–30 %) remains
idiopathic. Most of these studies have been performed over
15 years ago. More recent evidence suggests that the
prevalence of polyneuropathy in the general population has
increased over the years. Future research is necessary to
confirm this increase in prevalence and to identify new and
potentially modifiable risk factors.
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Introduction
Polyneuropathy is a peripheral neuropathy characterized by
symmetrical sensory symptoms, such as numbness, pares-
thesia and pain, and muscle weakness, which are pre-
dominantly located in the distal parts of arms and legs.
Polyneuropathy is a disabling disease and has a negative
impact on a person’s quality of life [1]. Although it is
assumed that polyneuropathy affects a considerable pro-
portion of the population, the exact prevalence and inci-
dence of the disease are not well known. Elderly probably
are at higher risk to develop polyneuropathy [2], and are
thus at higher risk for associated falls and related injuries.
Since an increasing proportion of the population is over
50 years of age, especially in developed countries, it is
important to recognize the disease and to screen for treat-
able causes. Information about the frequency of the disease
and its risk factors is therefore crucial.
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Over 100 different causes of polyneuropathy have been
identified, with diabetes as most important risk factor [2–
6]. Guidelines have been developed to distinguish between
these different causes [6–9]. Differentiation into acquired
versus inherited, chronic versus acute and axonal versus
demyelinating variants helps the diagnostic process in
clinical practice. Most polyneuropathies have a progres-
sive phase over months or years and have predominantly
axonal characteristics with reduced sensory and motor
nerve action potential amplitudes on electrophysiological
examination [2]. However, even when diagnostic guide-
lines in patients with a slowly progressive axonal neu-
ropathy are strictly applied, no cause can be identified in
about 20–30 % of patients. These patients are often
diagnosed with chronic idiopathic axonal neuropathy
(CIAP) [10].
The aim of this review is to summarize the literature
about the epidemiology of polyneuropathy and to obtain
more information about differences across populations and
between age groups. The review provides an overview of
studies that investigated the prevalence and incidence of
polyneuropathy and its associated risk factors.
Methods
Literature search
On January 8, 2015 (date last searched), we comprehen-
sively searched the literature, using electronic medical
databases (EMBASE, Medline, Web-of-science, Cochrane,
PubMed Publisher and Google Scholar), to identify pub-
lished studies reporting the prevalence or incidence of
polyneuropathy in the general population. Our search
strategy included a combination of terms about the disease
of interest (polyneuropathy, peripheral neuropathy) and
about epidemiology (epidemiology, prevalence, incidence).
The specific search terms for each database can be found in
the supplement. The search was limited to publications in
the English language. We did not use a limitation for
publication date. We initially selected publications that
reported prevalence or incidence of peripheral neuropathy
or polyneuropathy based on title and abstract. Studies that
only investigated specific patients groups without a control
group, for example only patients with diabetes, and studies
that only investigated specific neuropathies, such as auto-
nomic neuropathy, optic neuropathy, or mononeuropathy
were not included. Studies about peripheral neuropathy
were only included if the prevalence of polyneuropathy
was also specified. When multiple articles from the same
study were identified, the most recent or most compre-
hensive report was selected for this review. Our literature
search was complemented by reviewing the reference lists
of the identified articles, in order to gather other important
publications that were missed with our search terms.
In addition to the prevalence of polyneuropathy in
general, we further discuss some important risk factors for
polyneuropathy and the prevalence of chronic idiopathic
polyneuropathy. For this part of the review we also used
hospital-based studies that specified risk factors like dia-
betes or intoxications. Therefore, we searched Medline for
additional reports on frequency of different subtypes of
polyneuropathy. We used the following search term:
(neuropathy OR polyneuropathy OR neuropathies OR
polyneuropathies) AND (workup OR diagnostic investi-
gation OR cryptogenic OR idiopathic OR unspecified OR
unclassified OR undetermined) and used the same limita-
tions for this search as we did for the first one.
Data collection
The following information was extracted from the selected
studies: study size; geographical location (country); age
distribution of the study population; screening protocol
used; crude and, if available, standardized prevalence rates;
age- and sex specific prevalence rates; incidence rates;
cause-specific prevalence and, if possible, relative risks or
odds ratios for risk factors of polyneuropathy.
Results
Our search yielded 5119 articles, of which 3065 were
original articles. After excluding articles based on title or
abstract, and after reading the full-text of the remaining
articles, 28 studies remained. We included one additional
reference that was identified after reviewing the reference
lists of the selected articles. In total, 29 population-based
studies that reported on the frequency of polyneuropathy
were included in the review (Fig. 1). Twenty-eight studies
reported the prevalence, but only three reported the inci-
dence of polyneuropathy. One study only investigated the
incidence of polyneuropathy. The studies were divided into
three categories, based on study design: eleven door-to-
door survey studies [11–21], seven case–control studies
[22–28] and eleven cohort studies (seven cohort studies and
four database studies) [29–39].
Door-to-door survey studies (Table 1)
The World Health Organization (WHO) developed a pro-
tocol to study the epidemiology of major neurological
disorders, which was specifically designed for developing
countries where financial and medical resources are limited
[40]. This protocol consists of two stages. In the first stage,
a questionnaire to determine the presence of neurological
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symptoms and a brief examination to detect major neuro-
logical dysfunction are administered to the entire study
population. This stage is often carried out by non-medical
personnel (teachers, students, social workers) under
supervision of a nurse or a neurologist. In screen-positive
participants a neurologist performs a neurological exami-
nation to document the presence and type of the neuro-
logical disorder. The protocol includes screening for
headache, epilepsy, stroke and peripheral neuropathy,
among others. Peripheral neuropathy in this protocol
includes mononeuropathies, radiculopathy and polyneu-
ropathy. Only studies that specified the frequency of
polyneuropathy cases were included in this review.
Crude point prevalence of polyneuropathy in studies
using this, or a similar protocol, ranged from 0.8 to 32.5 per
1000 (0.1–3.3 %) persons across all ages [11–17, 19, 20].
When only elderly are studied, prevalence ranges from
18.8 to 200 per 1000 persons (1.9–20 %) [18, 21]. There is
a large variation in reported rates, but also in age distri-
bution across different study populations, study area and
study protocol (Table 1). Studies that report a low preva-
lence of polyneuropathy (0.8–2.5 per 1000) originate from
African and Middle Eastern countries, such as Nigeria [12,
14], and Saudi Arabia [16]. In these studies only 4–11 % of
the population is over the age of 50 years. In contrast, in
European countries such as Spain [13], where polyneu-
ropathy affects 7.3 per 1000 people, and in Albania [20],
where polyneuropathy is reported in 32.5 per 1000 people,
around 30 % is over 50 years of age. However, the latter
study used a different assessment protocol and was per-
formed 20 years after most of the other studies (Table 1).
Only two studies standardized the reported prevalence
rates to a reference population [20, 21]. Adjusting the
prevalence to the WHO world standard population resulted
in an adjusted prevalence of 23.6 per 1000 (crude 32.5 per
1000) in Albania [20] and of 18.6 per 1000 (crude 18.8 per
1000) in Tanzania [21].
Case–control studies (Table 2)
Seven reports compared the prevalence of polyneuropathy
in patients with diabetes or prediabetes to a non-diabetic
population-based sample of controls (Table 2) [22–28]. In
four of these studies, persons known with diabetes or
impaired glycemia were identified from medical databases
and invited to participate in the study [22, 23, 25, 28]. A
random sample of controls was selected from the same
community [22, 25, 28] or practice [23] and matched to the
diabetes patients on age [22, 23, 25, 28], sex [22, 23, 28]
and ethnicity [22]. The three remaining case–control
Records identified 
through databases  
(n = 5,119) 
Records after duplicates 
removed 
(n = 3,065) 
Records given full text 
assessment 
(n = 59) 
Records excluded based 
on title and abstract 
(n = 3,006) 
Studies included 
(n = 29)
Records identified 
through reference lists 
(n = 1) 
Full-text articles 
excluded 
(n = 31) 
- Background papers  
- Pilot studies  
- Multiple papers from one 
study 
- Various neuropathies, 
without specification 
‘polyneuropathy’ 
Records screened 
(n = 3,065) 
Fig. 1 Selection of 29 studies
that reported on the
epidemiology of
polyneuropathy
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Table 1 Door-to-door survey studies reporting prevalence of polyneuropathy
Study/country/
study year
Study
size
Age of the study
population
Assessment protocol Prevalence of
polyneuropathy
Prevalence of
polyneuropathy
related causes
(per 1000)
Cruz et al. [11]
Ecuador
1982
1113 All ages included;
[50 years: 18 %
WHO protocola Crude: 9.0 per 1000
Osuntokun et al. [12]
Nigeria
1982–1983
18,954 All ages included;
[50 years: 11 %
WHO protocol Crude: 2.5 per 1000 1.9 tropical
0.4 idiopathic
0.1 diabetic
0.1 hereditary
0.1 nutritional
Cruz Gutierrez-
del-Olmo et al. [13]
Spain
1984
961 All ages included;
[50 years: 30 %
WHO protocolb Crude: 7.3 per 1000 3.1 idiopathic
2.1 diabetic
2.1 alcoholic
Longe and Osuntokun [14]
Nigeria
1986
2925 All ages included;
[50 years: 10 %
WHO protocol Crude: 1.4 per 1000
Bharucha et al. [15]
India
1985
14,010 All ages included;
[50 years: 44 %
Adapted WHO protocol Crude: 7.1 per 1000 3.7 diabetic
2.1 idiopathic
0.4 toxic (alcohol
and iatrogenic)
0.3 inflammatory
0.1 hereditary
Al Rajeh et al. [16]
Saudi Arabia
1989
22,630 All ages included;
[50 years: 4 %
Adapted WHO protocol Crude: 0.8 per 1000
Savettieri et al. [17]
Italy
1993
14,540 All ages included;
[40 years: 40 %
Adapted WHO protocol Crude: 7 % screen positivec 2.1 diabetic
Lor et al. [18]
Malaysia
100 Only subjects[65
years included
Bilateral distal symptoms
and/or bilateral loss
of pinprick or joint
position sensation
Crude: 200 per 1000
Kandil et al. [19]
Egypt
1997
42,223 All ages included;
[50 years: 10 %
Adapted WHO protocol Crude: 8.3 per 1000 6.5 diabetic
0.9 idiopathic
0.5 metabolicd
0.2 inflammatory
0.1 hereditary
Kruja et al. [20]
Albania
2006–2008
9869 All ages included;
[50 years: 31 %
C2 symptoms ? bilateral impairment
of strength and/or sensation and/or
reflexes with symmetrical
distributione
Crude: 32.5 per 1000
Adjustedf: 23.6 per 1000
Dewhurst et al. [21]
Tanzania
2009–2010
2232 Only subjects
[70 years included
Self-developed two-phased screening
tool. First phase based on
questionnaire. Diagnosis according
to WHO definition
Crude; 18.8 per 1000
Adjustedf: 18.6 per 1000
Survey studies reporting prevalence of polyneuropathy. If reported, prevalence of polyneuropathy related causes is also shown
a WHO protocol: door-to-door screening with questionnaire and short examination, followed by a more comprehensive neurological exami-
nation performed by a neurologist to detect neurological disorders when screened positive in stage 1
b Protocol not specified, most likely WHO protocol
c Screening for all neuropathies, but only prevalence of diabetic neuropathy reported
d Including hypothyroidism, uremic and hepatic neuropathy
e Same protocol as Beghi et al. [29] (possible polyneuropathy criterion). Screening based on questionnaire, neurologist diagnosed polyneu-
ropathy according to given definition
f Age-standardized to the WHO world standard population
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studies included participants from population-based sur-
veys, where diabetes was assessed by self-report [24, 27] or
by an oral glucose tolerance test [26]. Controls were ran-
domly sampled from those without diabetes. Controls were
categorized into (new) diabetes, impaired glucose toler-
ance, impaired fasting glucose or normal glycemia
according to the results of an oral glucose tolerance test in
four studies [22, 26–28].
These studies reported a crude prevalence of polyneu-
ropathy in 7–42 % of patients with (newly diagnosed or
known) diabetes, in 6–13 % of patients with prediabetes
and in 2–13 % of controls. The main aim of these studies is
Table 2 Case–control (survey) studies reporting prevalence of polyneuropathy
Study/country/
study year
Selection of cases Selection of controls Number of
participants
Assessment protocol Definition of
polyneuropathy
Prevalence of
polyneuropathy
Franklin et al.
[22]
USA
1984–1986
Medical records from
hospitals and physicians,
and self-reports of persons
aged 20–74 years
Random sample of
households, matched on
age, sex and ethnicity.
Assessment with OGTT
DM: 277
IGT: 89
NGT: 486
Discomfort in the legs
Reflexes
Temperature sensation
C2 abnormal items DM: 25.8 %
IGT: 11.2 %
NGT: 3.5 %
Walters et al. [23]
UK
Medical records from 10
practices. All[ 30 years
of age
Non-diabetics without
glycosuria matched on
practice, sex and birthdate.
DM: 1077
No DM: 480
Symptoms (numbness,
burning, prickling,
aching, tingling), light
touch, pinprick, reflexes,
vibration perception
threshold
(biothesiometer)
C2 abnormal items DM: 16.3 %
No DM: 2.9 %
Harris et al. [24]
Finland
1979–1981
National Health Interview
Survey of people over
18 years. Self-reported
diabetes
Random sample from those
without diabetes
DM: 2829
No DM:
20,037
Numbness, pain or tingling,
decreased ability to feel
hot or cold
C1 symptom DM: 37.9 %
No DM: males
9.8, females
11.8 %a
Partanen et al.
[25]
Finland
1979–1981
Newly diagnosed diabetes
patients from district
health centers, aged
45–64 years, Exclusion
criteria: alcoholism,
thyroid dysfunction, renal
failure
Randomly selected controls
without diabetes from the
same age group, selected
from population registry.
Same exclusion criteria as
cases
New DM:
132
No DM: 142
Symptoms: bilateral
neuropathic pain,
paresthesia
Signs: atrophy, reflexes,
touch, pinprick, vibration
Nerve conduction velocity
and amplitude in
peroneal (4 values) and
sural nerves (2 values)
Definite: C4
abnormal NCS
values, including
peroneal and
sural nerve, and
symptoms
Probable: Same as
definite but
without
symptoms, or one
of the nerves
involved with
symptoms
Baseline:b
New DM: 8.3 %
No DM: 2.1 %
After 10 years:
New DM: 41.9 %
No DM: 5.8 %
Tapp et al. [26]
Australia
1999–2000
AusDiab survey study of
people[25 years of age.
Assessment with OGTT to
diagnose diabetes (and
evaluation of current
treatment)
Random sample of those
with normoglycemia after
OGTT
DM: 398
New DM:
423
IGT: 1009
IFG: 142
NGT: 464
Modified Neuropathy
Symptoms Score (NSS)
Modified Neuropathy
Disability Score (NDS)
Pressure perception test
(PPT) with monofilament
Postural blood pressure
drop
C2 of the scales
abnormal
(NSS[ 4,
NDS[ 5,
PPT\ 6,
fall in systolic
blood pressure of
C20 mmHg)
DM: 13.1 %
New DM: 7.1 %
IGT: 5.7 %
IFG: 5.6 %
NGT: 2.8 %
Ziegler et al. [27]
Germany
1997–1998
Participants with self-
reported diabetes from two
surveys of the MONICA/
KORA study, aged
24–74 years
Matched (age and sex)
nondiabetic subjects were
assessed with OGTT to
determine glycemic status
DM: 195
IGT: 46
IFG: 71
NGT: 81
Michigan Neuropathy
Screening Instrument
(MNSI)
MNSI[ 2 DM: 28.0 %
IGT: 13.0 %
IFG: 11.3 %
NGT: 7.4 %
Dyck et al. [28]
USA
2004
Patients known as having
impaired glycemia were
selected through databases
and assessed with OGTT
Patients known as having a
normal glucose, matched
on age and sex, were
assessed with OGTT
New DM:
218
IG: 174
NGT: 150
Neuropathy Symptoms and
Change (NSC)
Neuropathy Impairment
Score (NIS)
Composite scores of nerve
conduction
Clinical judgment
after abnormality
in nerve
conduction, NSC
or NIS
New DM: 17.4 %
IG: 12.6 %
NGT: 12.7 %
Case–control studies reporting prevalence of polyneuropathy in patients with diabetes, prediabetes and a population-based control group
OGTT oral glucose tolerance test, DM diabetes mellitusl, IGT impaired glucose tolerance, IFG impaired fasting glucose, NGT normal glucose
tolerance, IG impaired glycemia: IFG, IGT or impaired HbA1c
a Males 9.8 %, females 11.8 %. No numbers of total males and females are reported, average could not be calculated
b Probable and definite polyneuropathy are both considered polyneuropathy
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to show whether prevalence of polyneuropathy varies
across different stages of glycemic impairment and to
determine which determinants are associated with
polyneuropathy. Assessment methods, exclusion criteria
and polyneuropathy definitions across these studies differ
substantially (Table 2).
Cohort studies (Table 3)
Three cohort studies also compared the prevalence of
polyneuropathy in individuals with diabetes to individu-
als without diabetes [36–38]. However, in these studies
all members from a specific community were invited
before stratification on diabetes status, giving the
opportunity to also assess prevalence of polyneuropathy
in the whole population. In a study conducted in Canada,
an adult population with a very high prevalence of dia-
betes (29 %) was investigated and an overall crude
neuropathy prevalence of 7 % was reported [36]. Neu-
ropathy was defined as loss of monofilament sensation at
one or more sites on the feet in order to obtain a highly
sensitive, but not very specific, screening tool. The two
other studies were performed in China [37, 38].
Polyneuropathy was present in 13 % of adults of the She
ethnic minority group of China [37] and in 4 % of the
Han Chinese population over 25 years of age, free of
renal failure or type 1 diabetes [38]. These studies used
scoring systems (Toronto Clinical Neuropathy Scoring
System and Neuropathy Symptom Score with Neuropathy
Deficit Score respectively) to evaluate the presence of
polyneuropathy (Table 3).
In an effort to give a more precise population prevalence
estimate of polyneuropathy, a large study in two Italian
regions was conducted from 1990 to 1993. In this study
4191 subjects of 55 years and older, seen in General
Practitioners’ office consultations for any reason, were
investigated as a reflection of the general population [29].
Participants were screened with a 7-point yes/no screening
questionnaire (muscle cramps, restless legs, burning feet,
muscle pain, problems with object handling, impairment in
standing and gait, and paresthesia). The questionnaire was
pretested and validated in a hospital setting before initia-
tion of the study. In this validation study sensitivity and
specificity were 78 and 82 % respectively, using a cut-off
of two positive answers. After two or more positive
answers on the questionnaire, participants were examined
by a neurologist for signs of polyneuropathy. Possible
polyneuropathy (defined as neuropathic symptoms with
bilateral impairment in at least one of the following
modalities: strength, sensation or deep tendon reflexes) was
present in 7.3 % of participants and probable polyneu-
ropathy (symptoms and at least two abnormal modalities)
in 3.6 % of participants. The age- and sex-adjusted
prevalence rates for the two regions (adjusted to the 1990
Italian population) were 3.6 % for Varese and 3.3 % for
San Giovanni Rotondo.
In the Italian Longitudinal Study on Aging (ILSA), a
population-based cohort study, the prevalence of
polyneuropathy was also investigated (Table 3) [35].
Participants were randomly included from eight munici-
palities, based on population registries (704 participants
per municipality, 88 males and 88 females per 5-year age
group; range 65–84 years). The polyneuropathy screening
procedure consisted of an interview about symptoms
(‘‘have you ever had the feeling of burning pain and/or
numbness, or paresthesia in the feet or legs’’), a previous
neuropathy diagnosis (‘‘has a doctor ever told you that
you suffer from neuropathy of the legs’’) and drug treat-
ments and of a brief neurological examination (heel gait,
ankle tendon reflexes and touch and pain sensation),
administered by a clinical investigator. Individuals with a
self-reported diagnosis, at least one symptom, or at least
one abnormal test on the examination underwent a clini-
cal work up, which consisted of an evaluation of the
medical history, an extensive neurological examination
and a review of medical records. Nerve conduction
studies and laboratory investigations were not part of the
study protocol, but information about these measurements
was extracted from medical records if available. The
screening procedure had a sensitivity of 94.7 % and a
specificity of 70 % in a pilot study of 20 cases and 20
controls. The ILSA study reported an adjusted prevalence
of 7.0 % among 4500 participants aged 65–84 [35]. Three
years after the baseline investigation, 2845 participants
were screened for a second time with the same case-
finding procedure. This yielded an incidence rate of 7.9
per 1000 person-years.
Other studies that are listed in Table 3 include four
database studies [30–32, 39]. Two database studies used
hospital registries to identify patients with polyneu-
ropathy from a specific community [32, 39]. The other
two additionally used medical records and notes from
general practices [30, 31]. The diagnosis of polyneu-
ropathy was based on the clinical picture, comple-
mented with EMG according to local guidelines. In one
study, no polyneuropathy definition was reported [30].
With this database approach, only registered cases are
used to calculate prevalence or incidence rates, taking
the whole population of the community as the denom-
inator. The last two studies described in Table 3 include
one general practitioner study assessing elderly with a
less strict definition of polyneuropathy (at least one
bilateral peripheral neurological deficit) [33], and one
study investigating only idiopathic polyneuropathy in
Gulf war veterans [34].
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Age and sex-specific prevalence across all studies
Studies that reported age-specific prevalence rates consis-
tently showed a higher polyneuropathy prevalence in
higher age categories of the studied population [12, 15, 17,
19, 20, 27, 29, 35, 38, 39]. Crude sex-specific prevalence
rates are less consistent; most authors reported a higher
prevalence in females [15, 17, 19, 20, 35, 36], with a ratio
of 1.5–2:1. Two of these studies reported age-standardized,
sex-specific prevalence rates and showed that this female
predominance is not confounded by age [20, 35]. Other
studies found no difference [27, 38], or a slight opposite
result with a female:male ratio of about 1:1.4 [22, 39].
Risk factors for chronic polyneuropathy
Several diseases and factors have been associated with
polyneuropathy. Since polyneuropathy probably is a mul-
tifactorial disease, it is not entirely appropriate to attribute
the development of polyneuropathy to only one factor.
These factors should be considered as component causes,
and not as one sufficient cause. For instance, not all
patients with diabetes or alcoholism will develop
polyneuropathy, so multiple (known and unknown) com-
ponent causes probably contribute to the development of
the disease [41]. In clinical practice often one factor or
disease, such as diabetes or alcohol abuse, is considered as
a main (sufficient) cause of polyneuropathy in an individ-
ual. Some of the aforementioned survey studies sub-clas-
sified polyneuropathy according to these different causes.
Tropical neuropathies like leprosy are common causes of
polyneuropathy in developing countries such as Nigeria,
whereas diabetes is more common in countries or study
populations with a higher socio-economic status like Italy,
the Netherlands and Spain (Tables 1, 3). However, there is
not much population-based data available.
Several investigators studied causes of polyneuropathy
in hospital settings (Table 4) [32, 39, 42–48]. In all of these
studies, diabetes is the most common cause of polyneu-
ropathy, accounting for 18–49 % of all cases. Other known
important causes of polyneuropathy include alcohol abuse,
toxic agents, such as chemotherapeutic drugs, nutritional
deficiencies, immune-mediated causes and hereditary fac-
tors. Despite laboratory investigations, the cause in patients
with a chronic axonal polyneuropathy cannot be identified
in 12–49 %. Although there are probably some differences
in the etiology of these polyneuropathy subtypes, it is
likely that they share multiple common etiological factors.
Investigation of risk factors in specific subtypes is therefore
also important for polyneuropathy in general. Some of the
most common conditions related to polyneuropathy and
chronic idiopathic axonal polyneuropathy will be discussed
briefly.
Diabetic polyneuropathy
Prevalence of diabetes is 6.4 % worldwide and this number
is expected to rise the next decades [49]. Diabetes can lead
to several types of peripheral neuropathy, such as distal
symmetric polyneuropathy, autonomic neuropathy,
mononeuropathy and non-compressive radiculopathy.
Polyneuropathy is the most common presentation [50]. The
Italian General Practitioner Study Group reported a relative
risk of polyneuropathy associated with diabetes of 8.8
(95 % confidence interval 6.1–12.8) [51]. Polyneuropathy
occurs in up to 50 % of patients with diabetes and diabetes
accounts for 18–49 % of all polyneuropathy cases
(Table 4). Sensory symptoms are usually more prominent
than motor involvement and neuropathic pain is a common
disabling symptom, occurring in 40–60 % of patients with
diabetic neuropathy [50]. Diabetic polyneuropathy has an
axonal subtype in most cases. Treatment is mainly symp-
tomatic. Potential modifiable risk factors associated with
neuropathy in patients with diabetes include dyslipidemia,
hypertension and obesity [50, 52–56]. Whether these fac-
tors also contribute to the development of polyneuropathy
in non-diabetic subjects remains to be verified.
Alcoholic polyneuropathy
Polyneuropathy is reported to be present in 13–66 % of
chronic alcoholics, depending on diagnostic criteria used to
diagnose neuropathy [57, 58]. The relative risk of
polyneuropathy in chronic alcoholics is estimated at 3.9
(95 % confidence interval 1.5–9.0) [51]. There has been
debate whether neuropathy in alcoholics occurs due to
direct toxic effects of ethanol, due to a secondary thiamine
deficiency or due to a failure of tissues to utilize thiamine
in the presence of alcohol [57, 58]. Both alcoholic neu-
ropathy and thiamine-deficiency neuropathy are mainly of
the axonal type and are usually characterized by (painful)
sensory disturbance and weakness in the distal parts of the
lower extremities. Autonomic dysfunction often occurs.
There is accumulating evidence that there are differences in
the clinical phenotype between alcoholic neuropathy and
thiamine-deficiency neuropathy. Pure alcoholic neuropathy
without accompanying thiamine deficiency mainly affects
small fibers, leading to slowly progressive sensory-domi-
nant symptoms, neuropathic pain and impaired superficial
sensation, whereas thiamine-deficiency neuropathy pre-
dominantly affects large fibers, leading to a more pro-
gressive, or even acute, polyneuropathy with
predominantly motor symptoms [57, 58]. Since alcohol
abuse often coexists with nutritional deficiencies, com-
bined small and large fiber polyneuropathies are frequently
found. Treatment, other than alcohol cessation and
improvement of nutritional intake, is symptomatic.
The epidemiology and risk factors of chronic polyneuropathy 13
123
T
a
b
le
4
H
o
sp
it
al
-b
as
ed
st
u
d
ie
s
in
v
es
ti
g
at
ed
ca
u
se
s
o
f
p
o
ly
n
eu
ro
p
at
h
y
S
tu
d
y
G
eo
rg
e
an
d
T
w
o
m
ey
[4
2
]
L
in
et
al
.
[4
3
]
Jo
h
an
n
se
n
et
al
.
[4
4
]
M
y
g
la
n
d
et
al
.
[3
2
]
V
er
g
h
es
e
et
al
.
[4
5
]
R
o
se
n
b
er
g
et
al
.
[4
6
]
V
ra
n
ck
en
et
al
.
[4
7
]
R
u
d
o
lp
h
an
d
F
ar
b
u
[4
8
]
V
is
se
r
et
al
.
[3
9
]
C
o
u
n
tr
y
U
K
T
ai
w
an
D
en
m
ar
k
N
o
rw
ay
U
S
A
N
et
h
er
la
n
d
s
N
et
h
er
la
n
d
s
N
o
rw
ay
N
et
h
er
la
n
d
s
S
tu
d
y
p
er
io
d
1
9
8
0
–
1
9
8
4
1
9
8
8
–
1
9
8
9
1
9
9
3
–
1
9
9
9
1
9
9
9
1
9
9
0
–
1
9
9
9
1
9
9
3
–
1
9
9
7
1
9
9
9
–
2
0
0
2
2
0
0
0
–
2
0
0
5
2
0
1
0
P
o
p
u
la
ti
o
n
P
at
ie
n
ts
re
fe
rr
ed
to
h
o
sp
it
al
fo
r
N
C
S
P
at
ie
n
ts
se
en
in
5
n
eu
ro
lo
g
ic
al
ce
n
te
rs
P
at
ie
n
ts
re
fe
rr
ed
to
h
o
sp
it
al
fo
r
N
C
S
P
at
ie
n
ts
re
fe
rr
ed
to
h
o
sp
it
al
n
eu
ro
lo
g
is
t
P
at
ie
n
ts
re
fe
rr
ed
to
E
M
G
la
b
o
ra
to
ry
P
at
ie
n
ts
at
o
u
tp
at
ie
n
t
d
ep
ar
tm
en
t
M
u
lt
ic
en
te
r
st
u
d
y
o
f
p
at
ie
n
ts
w
it
h
a
d
ia
g
n
o
st
ic
w
o
rk
-
u
p
fo
r
P
N
P
P
at
ie
n
ts
re
fe
rr
ed
to
h
o
sp
it
al
n
eu
ro
lo
g
is
t
N
ew
h
o
sp
it
al
-
re
g
is
te
re
d
ca
se
s
N
u
m
b
er
o
f
p
at
ie
n
ts
7
4
5
2
0
1
4
7
1
9
2
2
3
1
1
7
1
1
7
2
1
3
7
2
2
6
7
4
3
A
g
e
C
6
5
–
1
8
–
7
0
–
6
5
–
7
5
C
7
5
2
6
–
9
3
C
1
8
9
–
9
2
C
1
8
A
ss
o
ci
a
te
d
ri
sk
fa
ct
o
r
(%
)
C
ry
p
to
g
en
ic
/C
IA
P
2
8
1
2
2
5
2
6
1
3
2
7
2
0
4
9
e
2
8
2
6
D
ia
b
et
es
2
7
4
9
3
2
1
9
4
6
3
1
3
8
2
6
1
8
3
2
M
al
ig
n
an
cy
1
3
2
1
4
3
4
1
3
3
In
fl
am
m
at
o
ry
1
1
8
2
8
7
4
1
4
1
6
9
f
T
o
x
ic
m
ed
ic
at
io
n
4
3
5
6
7
6
5
3
–
1
4
g
C
o
n
n
ec
ti
v
e
ti
ss
u
e
d
is
o
rd
er
/v
as
cu
li
ti
s
4
–
3
5
1
2
1
4
4
5
N
u
tr
it
io
n
al
d
efi
ci
en
cy
a
4
1
2
4
1
1
1
9
4
3
A
lc
o
h
o
l
3
9
1
9
1
0
6
1
9
6
1
0
1
4
g
R
en
al
fa
il
u
re
3
4
1
–
2
2
4
4
–
4
h
H
er
ed
it
ar
y
1
4
1
1
2
7
8
3
7
1
4
5
S
ar
co
id
o
si
s
1
–
–
2
–
–
1
–
–
–
H
y
p
o
th
y
ro
id
is
m
–
2
–
–
1
1
1
3
4
4
h
Is
ch
em
ic
–
2
1
–
0
2
–
–
–
–
P
ar
ap
ro
te
in
em
ia
–
2
5
4
1
4
1
9
–
–
L
iv
er
d
is
ea
se
–
1
–
–
–
–
–
–
1
–
In
fe
ct
io
n
b
–
–
1
1
0
1
1
–
2
–
C
ri
ti
ca
l
il
ln
es
s
–
–
1
–
3
4
1
–
–
–
H
IV
–
–
1
–
–
–
1
2
d
–
–
–
O
th
er
ca
u
se
s
–
2
3
c
–
2
3
–
–
–
–
a
In
cl
u
d
in
g
v
it
am
in
B
1
an
d
v
it
am
in
B
1
2
d
efi
ci
en
cy
b
In
fe
ct
io
n
in
cl
u
d
es
b
o
rr
el
ia
in
fe
ct
io
n
,
le
p
ro
sy
an
d
o
th
er
u
n
sp
ec
ifi
ed
in
fe
ct
io
n
s
c
2
%
u
n
sp
ec
ifi
ed
m
et
ab
o
li
c
d
is
o
rd
er
.
T
h
y
ro
id
d
y
sf
u
n
ct
io
n
n
o
t
re
p
o
rt
ed
d
H
IV
re
fe
rr
al
ce
n
te
r
e
L
ar
g
es
t
ce
n
te
r
is
a
C
IA
P
re
fe
rr
al
ce
n
te
r
f
In
fl
am
m
at
o
ry
n
eu
ro
p
at
h
ie
s
in
th
is
st
u
d
y
n
o
t
o
n
ly
in
cl
u
d
e
G
B
S
an
d
C
ID
P
,
b
u
t
al
so
p
o
ly
n
eu
ro
p
at
h
ie
s
as
so
ci
at
ed
w
it
h
p
ar
ap
ro
te
in
em
ia
,
p
ar
an
eo
p
la
st
ic
an
ti
b
o
d
ie
s/
m
al
ig
n
an
cy
an
d
H
IV
-
as
so
ci
at
ed
n
eu
ro
p
at
h
y
g
T
o
x
ic
m
ed
ic
at
io
n
an
d
al
co
h
o
l
ab
u
se
ar
e
co
m
b
in
ed
in
th
is
st
u
d
y
an
d
ac
co
u
n
ts
fo
r
1
4
%
h
T
h
y
ro
id
d
y
sf
u
n
ct
io
n
an
d
re
n
al
fu
n
ct
io
n
ar
e
co
m
b
in
ed
in
th
is
st
u
d
y
an
d
ac
co
u
n
ts
fo
r
4
%
14 R. Hanewinckel et al.
123
Hereditary polyneuropathy
Hereditary motor and sensory neuropathy, also called
Charcot–Marie–Tooth disease (CMT) is the most common
form of inherited peripheral neuropathy. CMT has an esti-
mated prevalence of 40–82 per 100,000 people [59, 60].
Mutations in genes encoding major structural proteins of
myelin, axonal transport andmitochondrialmetabolismhave
been described [60]. These genemutations ultimately lead to
slowly progressive weakness, wasting and sensory symp-
toms in distal body parts, starting at the feet. These patients
usually have high arches, hammer toes and weakness and
wasting of intrinsic muscles of the feet that will progress in
the lower legs in later stages of the disease. There are
demyelinating (CMT1, CMT3 and CMT4), axonal (CMT2)
and mixed or intermediate (CMTX and dominant interme-
diate CMT) types of CMT. Age of onset, severity and type of
symptoms, family history, presence of other neurological
signs (such as involvement of the central nervous system),
and especially nerve conduction studies can give clues to
determine the specific subtype and possibly involved genes.
No specific treatment is currently available [59].
Inflammatory neuropathies
Inflammatory neuropathies are reported in 2–16 % of all
polyneuropathy cases depending on the clinical setting of
the study (Table 4). Inflammatory neuropathies can present
as a rapidly progressive sensorimotor polyneuropathy with
a nadir within 4 weeks, known as the Guillain–Barre syn-
drome [61] and as a more chronic, relapsing-remitting or
gradually progressive polyneuropathy that develops over a
period of more than 8 weeks, as in chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP) [62].
CIDP is the most common chronic acquired demyeli-
nating polyneuropathy. Prevalence rates vary between 1
and 7 per 100,000 people, but this may be an underesti-
mation since the clinical presentation can be rather diverse,
leading to under diagnosis [62]. CIDP likely has an
autoimmune origin and is a treatable disorder. Patients can
be treated with intravenous immunoglobulins, steroids or
plasma exchange [62, 63].
Other causes
There are many more factors, such as vitamin B1 or B12
deficiency, paraproteins, connective tissue disorders (systemic
lupus erythematosus, Sjo¨gren’s syndrome) and toxic agents
(like chemotherapy) that are associated with polyneuropathy.
When patients over the age of 50 have a slowly progressive
symmetrical axonal polyneuropathy and no cause can be
established, these individuals are usually diagnosed as chronic
idiopathic axonal polyneuropathy (CIAP) [64–68].
Chronic idiopathic axonal polyneuropathy
CIAP occurs in 12–49 % of polyneuropathy cases
(Table 4), depending on the clinical setting (secondary
versus tertiary center, or referral center for specific dis-
eases). Precise population-based prevalence estimates are
lacking. A recent population-based database study from the
Netherlands reported that 26 % of incident polyneuropathy
cases were idiopathic. An incidence rate of 30.3/100,000
person-years for persons 40 years or older was found [39].
CIAP is characterized by an insidious onset of symptoms
usually starting in the sixth decade or later, and seems to
affect males more than females [10, 39, 64, 69]. Symptoms
are predominantly sensory, characterized by distal loss of
sensation (pain, numbness and tingling), with or without
weakness. The legs are more affected than the arms and
distribution is usually symmetrical. The disease is slowly
progressive and most patients remain ambulatory with mild
to moderate disability, but all patients experience a reduced
quality of life. Neurological examination shows decreased or
loss of vibration sense, diminished perception of pain and
light touch in a stocking like distribution and ankle reflexes
are often absent [64, 70]. Electrophysiological examination
shows features of an axonal polyneuropathy, usually with
reduced or absent sensory nerve action potentials of the sural
nerves and decreased amplitudes of the peroneal compound
motor action potential [64, 70]. Quantitative sensory testing
may show abnormal temperature and vibration thresholds
[70]. Diagnostic criteria have been developed to improve
recognition and diagnosis of CIAP [70].
CIAP probably constitutes of a heterogeneous group of
conditions. Current research suggests a role for the meta-
bolic syndrome, which includes impaired glucose toler-
ance, dyslipidemia, hypertension and obesity [65]. Studies
showed that the metabolic syndrome is an independent risk
factors for macro- and microvascular complications such as
retinopathy, nephropathy and neuropathy in patients with
diabetes [54, 71, 72]. Studies also showed that the meta-
bolic syndrome is more prevalent in patients with CIAP
[65, 73]. Impaired glucose metabolism probably is the most
important factor attributing to the development of
polyneuropathy, although results are not entirely consis-
tent. Independent associations with dyslipidemia and obe-
sity have also been reported [22, 27, 28, 65, 68, 73–80]. It
is likely however that yet undiscovered factors also con-
tribute to the development of CIAP.
Discussion
We identified 29 population-based studies that investigated
the epidemiology of polyneuropathy. There is a large
variation in reported prevalence rates across these studies
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(0.1–12.6 % across all ages, 1.9–30.9 % in elderly), which
is probably due to the diversity in assessment protocols,
definition of polyneuropathy, study populations and study
designs. Many studies rely on a two-step screening proto-
col. Participants are screened with a questionnaire, some-
times in combination with a short neurological
examination, and only screen-positive participants are
examined by a trained physician, usually a neurologist. In
order to get a valid estimate of the prevalence of a disease,
this first stage should identify all cases as screen-positive
(sensitivity should be 100 %). A low number of screen
positive participants without disease (high specificity) is
also preferred, especially when resources and time are
limited. Studies that do not use a two-step approach, but
only use symptoms or signs, or a combination of both into a
component score as diagnostic protocol need to be both
sensitive and specific in order to obtain a valid estimate of
the prevalence.
Most information is derived from door-to-door survey
studies. An advantage of these studies is that similar
research protocols have been used in large study popula-
tions and that the diagnostics can be done with relatively
few resources. These studies give insight in the epidemi-
ology of several neurological disorders, but may underes-
timate the prevalence of polyneuropathy, since subclinical
polyneuropathy can be missed and refusal to participate in
the study may give rise to selection bias. As these studies
were not primarily focused on polyneuropathy and did not
include an extensive neuropathy work-up, including nerve
conduction studies, the results highly depend on the sen-
sitivity of the screening procedure in the first stage, which
is often not optimal. Despite this, most studies report a high
sensitivity for the entire screening protocol. Overall,
prevalence of polyneuropathy in door-to-door survey
studies from developed countries seems higher than in
studies performed in developing countries. This may partly
be explained by a larger proportion of elderly people
included in studies from developed countries. Standardiz-
ing prevalence to the same reference population is helpful
to investigate this confounding effect of age, but unfortu-
nately not many studies have standardized their prevalence
rates. Other reasons for this variation can be differences in
genetic, socioeconomic and environmental factors and
differences in prevalence of associated risk factors for
neuropathy. For example, alcohol consumption is consid-
ered to be less common in most developing countries [81],
and prevalence of diabetes is lower, especially in Africa
[49].
The case–control studies that were identified were pri-
marily focused on determining an association between
diabetes, prediabetes and neuropathy. Although these case–
control studies give an estimate of the occurrence of non-
diabetic polyneuropathy in controls, they are not suitable to
give a population prevalence of polyneuropathy, because
the distribution of cases and controls likely differs from the
general population. Although three other studies included
all inhabitants from a specific community [36–38] before
stratifying for diabetes, the assessment methods (with low
sensitivity or low specificity), exclusion criteria or low
participation rate, indicate that the population prevalence
estimates are most likely overestimated or biased.
The four database studies that investigated the frequency
of polyneuropathy probably all underestimate the true inci-
dence or prevalence, since only previously diagnosed
patients were identified in these studies. Symptomatic indi-
viduals who do not visit a doctor, asymptomatic individuals,
and individuals not being referred to a hospital (in case of
hospital-based database studies) because there is a clear
cause for the complaints (e.g. diabetes) are missed with this
approach. The cohort study performed by the Italian General
Practitioner Study Group was one of the first extensive
community studies specifically designed to investigate
polyneuropathy in an unselected elderly population. A
‘probable’ neuropathy was present in 4 % and a ‘possible’
polyneuropathy was diagnosed in 7 % of the participants
who visited their general practitioner [29]. The results found
in this study might lack validity due to selection bias. On the
one hand, patients who visit a general practitioner may be
less healthy and at a higher risk for polyneuropathy, due to
chronic diseases or medication use, leading to an overesti-
mated prevalence rate. On the other hand, some persons who
have an increased risk to develop neuropathy, such as alco-
holics or severely impaired patients, might be less likely to
visit a general practitioner, leading to an underestimation of
the prevalence. An unselected sample of 93 patients from the
same general practitioners was visited and assessed at home.
In this small sample, probable polyneuropathywas present in
4.3 %. This suggest a modest underestimation in the
screened population (3.6 %). However, prevalence might
also be underestimated, because only symptomatic patients
were included in the study and sensitivity of the screening
instrument was only 78 %. Moreover, nerve conduction
studies were not performed.
The ILSA study reported a prevalence of polyneuropathy
in persons over 65 years of age of 7 % [35]. Participants
were randomly selected from database registries, probably
leading to an unbiased and random sample of the general
population. The case-finding procedure had a desirably high
sensitivity and did not only rely on symptoms. This prob-
ably resulted in the most unbiased and reliable estimate of
the prevalence of chronic polyneuropathy in the general
elderly population. However, nerve conduction studies
were not part of the study protocol and no polyneuropathy
work-up, including laboratory investigations, was per-
formed. Therefore, detailed information about causes and
subtypes of polyneuropathy was not available.
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Both these cohort studies reported a polyneuropathy
prevalence of around 7 % [29, 35],which is much higher
than the rates found in the door-to-door surveys, which are
close to 1 % [13]. In the two Italian cohorts only elderly
were included and the screening protocols were primarily
focused on the detection of polyneuropathy, whereas most
survey studies screened for a variety of neurological dis-
orders across all ages. This might explain the higher
prevalence found in these cohort studies.
Almost all before mentioned studies, including the ILSA
study, were performed fifteen to 20 years ago. Since that
time, life-expectancy, the proportion of elderly in the
population and prevalence of obesity and diabetes
increased [49, 82]. Perhaps this resulted in an increase in
the incidence of polyneuropathy as well, which is also
suggested by the results of the survey study performed in
Albania from 2006 to 2008 [20]. This study reported a
polyneuropathy prevalence of 3 % in the total general
population (including all age categories), using a similar
screening method as the Italian General Practitioner Study
Group. Whether polyneuropathy is truly more prevalent
than it was 20 years ago has to be confirmed in properly
designed, large population-based studies.
Conclusions and future directions
Prevalence of polyneuropathy in the general population
ranges from 1 to 3 % and increases to 7 % in the elderly.
Prevalence seems to depend on socioeconomic status and
the age distribution of the study population. In developing
countries the prevalence is lower, which can possibly be
explained by a smaller proportion of elderly in the popu-
lation and by differences in the prevalence of polyneu-
ropathy risk factors. Life-expectancy and prevalence of
associated risk factors have increased in the last decades.
Whether this resulted in more patients with polyneuropathy
is yet unknown. There is a need for more, properly
designed, large studies that investigate the prevalence and
risk factors of polyneuropathy in the general population. A
cohort study of a general, unselected population would be
the most ideal study design to give an unbiased estimate of
the prevalence and incidence of polyneuropathy. Popula-
tion surveys may also be used, but in general, available
data and case definitions in these studies are less detailed
than in cohort studies. To assess risk factors for polyneu-
ropathy, case–control studies may be more efficient than
cohort studies, but may also be more prone to biases.
Heterogeneity in polyneuropathy definitions in past studies
makes comparison between studies difficult. To overcome
this, future studies should use a similar definition and
screening protocol for polyneuropathy. Unfortunately, a
gold standard test for polyneuropathy does not exist. A
combination of neuropathic symptoms, neuropathic signs
and abnormal nerve conduction studies provides the most
accurate diagnosis of polyneuropathy. Therefore investi-
gating prevalence of polyneuropathy in a large population
is challenging. Ideally, new studies should uniformly
include all these three aspects [7]. Standardizing results to
a reference population is encouraged in order to ease
comparison between studies.
Hopefully, future large prospective cohort studies that
assess the presence of chronic diseases together with car-
diovascular, metabolic, hereditary and lifestyle factors will
also focus on disorders of the peripheral nervous system.
These studies should also incorporate the assessment of
polyneuropathy both cross-sectionally and longitudinally
during follow-up over the years. This will hopefully give
insight into new risk factors for this disabling condition.
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